Colorectal cancer prevention: Is an ounce of prevention worth a pound of cure?

Seminars in Oncology

Volumn 32, Issue 1 SPEC. ISS., 2005, Pages 24-34

  Gill, Sharlene ^a   Sinicrope, Frank A ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CALCIUM; CELECOXIB; EFLORNITHINE; ESTROGEN; FOLIC ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM; PRAVASTATIN; ROFECOXIB; SELENIUM; SIMVASTATIN; SULINDAC SULFIDE; URSODEOXYCHOLIC ACID;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BREAST CANCER; CANCER EPIDEMIOLOGY; CANCER PREVENTION; CANCER RISK; CANCER SURVIVAL; CARDIOTOXICITY; CELL PROLIFERATION; CLINICAL TRIAL; COLONOSCOPY; COLORECTAL CANCER; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DRUG COST; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; ESTROGEN THERAPY; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL TOXICITY; GENE DELETION; HIGH RISK POPULATION; HUMAN; ISCHEMIC HEART DISEASE; META ANALYSIS; OTOTOXICITY; POSTMENOPAUSE; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; RISK REDUCTION; SIDE EFFECT; SIGMOIDOSCOPY; STROKE; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT WITHDRAWAL; VITAMIN SUPPLEMENTATION;

EID: 13844269344     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2004.09.038     Document Type: Article

References (122)

1. T. Tiwari, T. Murray Cancer statistics, 2004 CA Cancer J Clin 54 2004 8 29
2. NCI-C National Cancer Institute of Canada, Canadian Cancer Statistics 2003 www.cancer.ca
3. B. Vogelstein, E.R. Fearon, S.R. Hamilton Genetic alterations during colorectal-tumor development N Engl J Med 319 1988 525 532
4. S.N. Thibodeau, G. Bren, D. Schaid Microsatellite instability in cancer of the proximal colon Science 260 1993 816 819
5. R. Gryfe, H. Kim, E.T. Hsieh Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer N Engl J Med 342 2000 69 77
6. H.T. Lynch, T. Smyrk, J. Lynch An update of HNPCC (Lynch syndrome) Cancer Genet Cytogenet 93 1997 84 99
7. L.A. Aaltonen, R. Salovaara, P. Kristo Incidence of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening for the disease N Engl J Med 338 1998 1481 1487
8. A.R. Williams, B.A. Balasooriya, D.W. Day Polyps and cancer of the large bowel A necropsy study in Liverpool Gut 23 1982 835 842
9. S.J. Winawer, A.G. Zauber, M.N. Ho The National Polyp Study Workgroup Prevention of colorectal cancer by colonoscopic polypectomy N Engl J Med 329 1993 1977 1981
10. J.L. Viner, A. Umar, E.T. Hawk Chemoprevention of colorectal cancer Problems, progress, and prospects Gastroenterol Clin North Am 31 2002 971 999
11. R.W. Burt, D.T. Bishop, L.A. Cannon Dominant inheritance of adenomatous colonic polyps and colorectal cancer N Engl J Med 312 1985 1540 1544
12. W.R. Waddell, G.F. Ganser, E.J. Cerise Sulindac for polyposis of the colon Am J Surg 157 1989 175 179
13. M.J. Thun, M.M. Namboodiri, C.W. Heath Jr Aspirin use and reduced risk of fatal colon cancer N Engl J Med 325 1991 1593 1596
14. E. Giovannucci, E.B. Rimm, M.J. Stampfer Aspirin use and the risk for colorectal cancer and adenoma in male health professionals Ann Intern Med 121 1994 241 246
15. E. Giovannucci, K.M. Egan, D.J. Hunter Aspirin and the risk of colorectal cancer in women N Engl J Med 333 1995 609 614
16. T. Sturmer, R.J. Glynn, I.M. Lee Aspirin use and colorectal cancer Post-trial follow-up data from the Physicians' Health Study Ann Intern Med 128 1998 713 720
17. W. Smalley, W.A. Ray, J. Daugherty Use of nonsteroidal anti-inflammatory drugs and incidence of colorectal cancer A population-based study Arch Intern Med 159 1999 161 166
18. A.T. Chan, E.L. Giovannucci, E.S. Schernhammer A prospective study of aspirin use and the risk for colorectal adenoma Ann Intern Med 140 2004 157 166
19. H.R. Herschman, W. Xie, S. Reddy Inflammation, reproduction, cancer and all that.... The regulation and role of the inducible prostaglandin synthase Bioessays 17 1995 1031 1037
20. C.E. Eberhart, R.J. Coffey, A. Radhika Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas Gastroenterology 107 1994 1183 1188
21. F.A. Sinicrope, M. Lemoine, L. Xi Reduced expression of cyclooxygenase 2 proteins in hereditary nonpolyposis colorectal cancers relative to sporadic cancers Gastroenterology 117 1999 350 358
22. G.A. FitzGerald, C. Patrono The coxibs, selective inhibitors of cyclooxygenase-2 N Engl J Med 345 2001 433 442
23. M. Oshima, J.E. Dinchuk, S.L. Kargman Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2) Cell 87 1996 803 809
24. T. Kawamori, C.V. Rao, K. Seibert Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis Cancer Res 58 1998 409 412
25. R.F. Jacoby, D.J. Marshall, M.A. Newton Chemoprevention of spontaneous intestinal adenomas in the Apc Min mouse model by the nonsteroidal anti-inflammatory drug piroxicam Cancer Res 56 1996 710 714
26. N.N. Mahmoud, S.K. Boolbol, A.J. Dannenberg The sulfide metabolite of sulindac prevents tumors and restores enterocyte apoptosis in a murine model of familial adenomatous polyposis Carcinogenesis 19 1998 87 91
27. M. Oshima, N. Murai, S. Kargman Chemoprevention of intestinal polyposis in the Apcdelta716 mouse by rofecoxib, a specific cyclooxygenase-2 inhibitor Cancer Res 61 2001 1733 1740
28. R.A. Gupta, R.N. DuBois Aspirin, NSAIDS, and colon cancer prevention mechanisms? Gastroenterology 114 1998 1095 1098
29. Y. Sun, X.M. Tang, E. Half Cyclooxygenase-2 overexpression reduces apoptotic susceptibility by inhibiting the cytochrome c-dependent apoptotic pathway in human colon cancer cells Cancer Res 62 2002 6323 6328
30. A. Bedi, P.J. Pasricha, A.J. Akhtar Inhibition of apoptosis during development of colorectal cancer Cancer Res 55 1995 1811 1816
31. R. Yamazaki, N. Kusunoki, T. Matsuzaki Selective cyclooxygenase-2 inhibitors show a differential ability to inhibit proliferation and induce apoptosis of colon adenocarcinoma cells FEBS Lett 531 2002 278 284
32. S. Grosch, I. Tegeder, E. Niederberger COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib FASEB J 15 2001 2742 2744
33. S.J. Shiff, L. Qiao, L.L. Tsai Sulindac sulfide, an aspirin-like compound, inhibits proliferation, causes cell cycle quiescence, and induces apoptosis in HT-29 colon adenocarcinoma cells J Clin Invest 96 1995 491 503
34. G.A. Piazza, A.L. Rahm, M. Krutzsch Antineoplastic drugs sulindac sulfide and sulfone inhibit cell growth by inducing apoptosis Cancer Res 55 1995 3110 3116
35. X. Tang, Y.J. Sun, E. Half Cyclooxygenase-2 overexpression inhibits death receptor 5 expression and confers resistance to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human colon cancer cells Cancer Res 62 2002 4903 4908
36. Y. Huang, Q. He, M.J. Hillman Sulindac sulfide-induced apoptosis involves death receptor 5 and the caspase 8-dependent pathway in human colon and prostate cancer cells Cancer Res 61 2001 6918 6924
37. L. Zhang, J. Yu, B.H. Park Role of BAX in the apoptotic response to anticancer agents Science 290 2000 989 992
38. D.J. Elder, D.E. Halton, A. Hague Induction of apoptotic cell death in human colorectal carcinoma cell lines by a cyclooxygenase-2 (COX-2)-selective nonsteroidal anti-inflammatory drug Independence from COX-2 protein expression Clin Cancer Res 3 1997 1679 1683
39. G.G. Sheng, J. Shao, H. Sheng A selective cyclooxygenase 2 inhibitor suppresses the growth of H-ras-transformed rat intestinal epithelial cells Gastroenterology 113 1997 1883 1891
40. H.S. Samaha, G.J. Kelloff, V. Steele Modulation of apoptosis by sulindac, curcumin, phenylethyl-3- methylcaffeate, and 6-phenylhexyl isothiocyanate Apoptotic index as a biomarker in colon cancer chemoprevention and promotion Cancer Res 57 1997 1301 1305
41. P.J. Morin, B. Vogelstein, K.W. Kinzler Apoptosis and APC in colorectal tumorigenesis Proc Natl Acad Sci U S A 93 1996 7950 7954
42. J.J. Keller, G.J. Offerhaus, M. Polak Rectal epithelial apoptosis in familial adenomatous polyposis patients treated with sulindac Gut 45 1999 822 828
43. J.J. Keller, G.J. Offerhaus, L.M. Hylind Rectal epithelial apoptosis does not predict response to sulindac treatment or polyp development in presymptomatic familial adenomatous polyposis patients Cancer Epidemiol Biomarkers Prev 11 2002 670 671
44. F.A. Sinicrope, E. Half, J.S. Morris Cell proliferation and apoptotic indices predict adenoma regression in a placebo-controlled trial of celecoxib in familial adenomatous polyposis (FAP) patients Cancer Epidemiol Biomarkers Prev 3 2004 1 8
45. M. Tsujii, S. Kawano, R.N. DuBois Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential Proc Natl Acad Sci U S A 94 1997 3336 3340
46. J.L. Masferrer, K.M. Leahy, A.T. Koki Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors Cancer Res 60 2000 1306 1311
47. M. Tsujii, S. Kawano, S. Tsuji Cyclooxygenase regulates angiogenesis induced by colon cancer cells Cell 93 1998 705 716
48. R. Hanif, A. Pittas, Y. Feng Effects of nonsteroidal anti-inflammatory drugs on proliferation and on induction of apoptosis in colon cancer cells by a prostaglandin-independent pathway Biochem Pharmacol 52 1996 237 245
49. M.A. Molina, M. Sitja-Arnau, M.G. Lemoine Increased cyclooxygenase-2 expression in human pancreatic carcinomas and cell lines Growth inhibition by nonsteroidal anti-inflammatory drugs Cancer Res 59 1999 4356 4362
50. G.A. Piazza, D.S. Alberts, L.J. Hixson Sulindac sulfone inhibits azoxymethane-induced colon carcinogenesis in rats without reducing prostaglandin levels Cancer Res 57 1997 2909 2915
51. D.S. Alberts, L. Hixson, D. Ahnen Do NSAIDs exert their colon cancer chemoprevention activities through the inhibition of mucosal prostaglandin synthetase? J Cell Biochem 22 suppl 1995 18 23
52. C.S. Williams, A.J. Watson, H. Sheng Celecoxib prevents tumor growth in vivo without toxicity to normal gut Lack of correlation between in vitro and in vivo models Cancer Res 60 2000 6045 6051
53. E. Kopp, S. Ghosh Inhibition of NF-kappa B by sodium salicylate and aspirin Science 265 1994 956 959
54. J.M. Lehmann, J.M. Lenhard, B.B. Oliver Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs J Biol Chem 272 1997 3406 3410
55. T.C. He, T.A. Chan, B. Vogelstein PPARdelta is an APC-regulated target of nonsteroidal anti-inflammatory drugs Cell 99 1999 335 345
56. F.M. Giardiello, S.R. Hamilton, A.J. Krush Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis N Engl J Med 328 1993 1313 1316
57. G. Steinbach, P.M. Lynch, R.K. Phillips The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis N Engl J Med 342 2000 1946 1952
58. F.M. Giardiello, V.W. Yang, L.M. Hylind Primary chemoprevention of familial adenomatous polyposis with sulindac N Engl J Med 346 2002 1054 1059
59. R.S. Sandler, S. Halabi, J.A. Baron A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer N Engl J Med 348 2003 883 890
60. J.A. Baron, B.F. Cole, R.S. Sandler A randomized trial of aspirin to prevent colorectal adenomas N Engl J Med 348 2003 891 899
61. D. Sample, M. Wargovich, S.M. Fischer A dose-finding study of aspirin for chemoprevention utilizing rectal mucosal prostaglandin E(2) levels as a biomarker Cancer Epidemiol Biomarkers Prev 11 2002 275 279
62. R. Benamouzig, J. Deyra, A. Martin Daily soluble aspirin and prevention of colorectal adenoma recurrence One-year results of the APACC trial Gastroenterology 125 2003 328 336
63. U. Ladabaum, C.L. Chopra, G. Huang Aspirin as an adjunct to screening for prevention of sporadic colorectal cancer. A cost-effectiveness analysis Ann Intern Med 135 2001 769 781
64. S. Suleiman, D.K. Rex, A. Sonnenberg Chemoprevention of colorectal cancer by aspirin A cost-effectiveness analysis Gastroenterology 122 2002 78 84
65. M. Hayden, M. Pignone, C. Phillips Aspirin for the primary prevention of cardiovascular events: A summary of the evidence for the U.S. Preventive Services Task Force Ann Intern Med 136 2002 161 172
66. W.G. Bensen, S.Z. Zhao, T.A. Burke Upper gastrointestinal tolerability of celecoxib, a COX-2 specific inhibitor, compared to naproxen and placebo J Rheumatol 27 2002 1876 1883
67. F.E. Silverstein, G. Faich, J.L. Goldstein Gastrointestinal toxicity with celecoxib vs nonsteroidal anti- inflammatory drugs for osteoarthritis and rheumatoid arthritis: The CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study JAMA 284 2000 1247 1255
68. J.L. Goldstein, F.E. Silverstein, N.M. Agrawal Reduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX-2 inhibitor Am J Gastroenterol 95 2000 1681 1690
69. F.K. Chan, L.C. Hung, B.Y. Suen Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis N Engl J Med 347 2002 2104 2110
70. W.A. Ray, C.M. Stein, J.R. Daugherty COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease Lancet 360 2002 1071 1073
71. D. Mukherjee, S.E. Nissen, E.J. Topol Risk of cardiovascular events associated with selective COX-2 inhibitors JAMA 286 2001 954 959
72. N.E. Newton, M.M. Abdel-Monem Inhibitors of polyamine biosynthesis. 4. Effects of alpha-methyl-(+/-)-ornithine and methylglyoxal bis(guanylhydrazone) on growth and polyamine content of L1210 leukemic cells of mice J Med Chem 20 1977 249 253
73. P. Pohjanpelto, E. Holtta, O.A. Janne Amplification of ornithine decarboxylase gene in response to polyamine deprivation in Chinese hamster ovary cells J Biol Chem 260 1985 8532 8537
74. G.D. Luk, S.B. Baylin Ornithine decarboxylase as a biologic marker in familial colonic polyposis N Engl J Med 311 1984 80 83
75. J. Rozhin, P.S. Wilson, A.W. Bull Ornithine decarboxylase activity in the rat and human colon Cancer Res 44 1984 3226 3230
76. L.J. Hixson, H.S. Garewal, D.L. McGee Ornithine decarboxylase and polyamines in colorectal neoplasia and mucosa Cancer Epidemiol Biomarkers Prev 2 1993 369 374
77. C. Bello-Fernandez, G. Packham, J.L. Cleveland The ornithine decarboxylase gene is a transcriptional target of c-Myc Proc Natl Acad Sci U S A 90 1993 7804 7808
78. L.H. Augenlicht, S. Wadler, G. Corner Low-level c-myc amplification in human colonic carcinoma cell lines and tumors A frequent, p53-independent mutation associated with improved outcome in a randomized multi-institutional trial Cancer Res 57 1997 1769 1775
79. T.C. He, A.B. Sparks, C. Rago Identification of c-MYC as a target of the APC pathway Science 281 1998 1509 1512
80. S.H. Erdman, N.A. Ignatenko, M.B. Powell APC-dependent changes in expression of genes influencing polyamine metabolism, and consequences for gastrointestinal carcinogenesis, in the Min mouse Carcinogenesis 20 1999 1709 1713
81. F.L. Meyskens Jr, E.W. Gerner Development of difluoromethylornithine (DFMO) as a chemoprevention agent Clin Cancer Res 5 1999 945 951
82. W. Wang, L.Q. Liu, C.M. Higuchi Mucosal polyamine measurements and colorectal cancer risk J Cell Biochem 63 1996 252 257
83. F.L. Meyskens Jr, E.W. Gerner, S. Emerson Effect of alpha- difluoromethylornithine on rectal mucosal levels of polyamines in a randomized, double-blinded trial for colon cancer prevention J Natl Cancer Inst 90 1998 1212 1218
84. R.F. Jacoby, C.E. Cole, K. Tutsch Chemopreventive efficacy of combined piroxicam and difluoromethylornithine treatment of Apc mutant Min mouse adenomas, and selective toxicity against Apc mutant embryos Cancer Res 60 2000 1864 1870
85. H. Li, H.A. Schut, P. Conran Prevention by aspirin and its combination with alpha-difluoromethylornithine of azoxymethane-induced tumors, aberrant crypt foci and prostaglandin E2 levels in rat colon Carcinogenesis 20 1999 425 430
86. M.E. Martinez, T.G. O'Brien, K.E. Fultz Pronounced reduction in adenoma recurrence associated with aspirin use and a polymorphism in the ornithine decarboxylase gene Proc Natl Acad Sci U S A 100 2003 7859 7864
87. E.E. Deschner, B.I. Cohen, R.F. Raicht Acute and chronic effect of dietary cholic acid on colonic epithelial cell proliferation Digestion 21 1981 290 296
88. T. Hori, K. Matsumoto, Y. Sakaitani Effect of dietary deoxycholic acid and cholesterol on fecal steroid concentration and its impact on the colonic crypt cell proliferation in azoxymethane-treated rats Cancer Lett 124 1998 79 84
89. B.I. Cohen, R.F. Raicht, E.E. Deschner Effect of cholic acid feeding on N-methyl-N-nitrosourea-induced colon tumors and cell kinetics in rats J Natl Cancer Inst 64 1980 573 578
90. J. Stadler, K.S. Yeung, R. Furrer Proliferative activity of rectal mucosa and soluble fecal bile acids in patients with normal colons and in patients with colonic polyps or cancer Cancer Lett 38 1988 315 320
91. T. Narisawa, Y. Fukaura, K. Terada Inhibitory effects of ursodeoxycholic acid on N-methylnitrosourea-induced colon carcinogenesis and colonic mucosal telomerase activity in F344 rats J Exp Clin Cancer Res 18 1999 259 266
92. D.L. Earnest, H. Holubec, R.K. Wali Chemoprevention of azoxymethane-induced colonic carcinogenesis by supplemental dietary ursodeoxycholic acid Cancer Res 54 1994 5071 5074
93. D.S. Pardi, E.V. Loftus Jr, W.K. Kremers Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis Gastroenterology 124 2003 889 893
94. D.S. Alberts, M.E. Martinez, D. Roe Proving the bile acid hypothesis for colon carcinogenesis Mature results from a phase III chemoprevention trial of ursodeoxycholic acid versus placebo to prevent colorectal adenoma recurrence Proc Am Soc Clin Oncol 22 2003 91 (abstr 363)
95. T.R. Pedersen, K. Berg, T.J. Cook Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the Scandinavian Simvastatin Survival Study Arch Intern Med 156 1996 2085 2092
96. F.M. Sacks, M.A. Pfeffer, L.A. Moye The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators N Engl J Med 335 1996 1001 1009
97. T. Narisawa, Y. Fukaura, K. Terada Prevention of 1,2-dimethylhydrazine- induced colon tumorigenesis by HMG-CoA reductase inhibitors, pravastatin and simvastatin, in ICR mice Carcinogenesis 15 1994 2045 2048
98. B. Agarwal, C.V. Rao, S. Bhendwal Lovastatin augments sulindac-induced apoptosis in colon cancer cells and potentiates chemopreventive effects of sulindac Gastroenterology 117 1999 838 847
99. E.E. Calle, H.L. Miracle-McMahill, M.J. Thun Estrogen replacement therapy and risk of fatal colon cancer in a prospective cohort of postmenopausal women J Natl Cancer Inst 87 1995 517 523
100. F. Grodstein, M.E. Martinez, E.A. Platz Postmenopausal hormone use and risk for colorectal cancer and adenoma Ann Intern Med 128 1998 705 712
101. C. Campagnoli, N. Biglia, F. Altare Differential effects of oral conjugated estrogens and transdermal estradiol on insulin-like growth factor 1, growth hormone and sex hormone binding globulin serum levels Gynecol Endocrinol 7 1993 251 258
102. A.J. McMichael, J.D. Potter Reproduction, endogenous and exogenous sex hormones, and colon cancer A review and hypothesis J Natl Cancer Inst 65 1980 1201 1207
103. J.E. Rossouw, G.L. Anderson, R.L. Prentice Risks and benefits of estrogen plus progestin in healthy postmenopausal women Principal results From the Women's Health Initiative randomized controlled trial JAMA 288 2002 321 333
104. J. Hyman, J.A. Baron, B.J. Dain Dietary and supplemental calcium and the recurrence of colorectal adenomas Cancer Epidemiol Biomarkers Prev 7 1998 291 295
105. M.E. Martinez, W.C. Willett Calcium, vitamin D, and colorectal cancer A review of the epidemiologic evidence Cancer Epidemiol Biomarkers Prev 7 1998 163 168
106. J.A. Baron, M. Beach, J.S. Mandel Calcium Polyp Prevention Study Group Calcium supplements for the prevention of colorectal adenomas N Engl J Med 340 1999 101 107
107. M.V. Grau, J.A. Baron, R.S. Sandler Vitamin D, calcium supplementation, and colorectal adenomas Results of a randomized trial J Natl Cancer Inst 95 2003 1765 1771
108. S.A. Lamprecht, M. Lipkin Chemoprevention of colon cancer by calcium, vitamin D and folate molecular mechanisms Nat Rev Cancer 3 2003 601 614
109. E. Giovannucci, M.J. Stampfer, G.A. Colditz Multivitamin use, folate, and colon cancer in women in the Nurses' Health Study Ann Intern Med 129 1998 517 524
110. C.S. Fuchs, W.C. Willett, G.A. Colditz The influence of folate and multivitamin use on the familial risk of colon cancer in women Cancer Epidemiol Biomarkers Prev 11 2002 227 234
111. J.A. Baron, R.S. Sandler, R.W. Haile Folate intake, alcohol consumption, cigarette smoking, and risk of colorectal adenomas J Natl Cancer Inst 90 1998 57 62
112. D.S. Alberts, M.E. Martinez, D.J. Roe Lack of effect of a high-fiber cereal supplement on the recurrence of colorectal adenomas. Phoenix Colon Cancer Prevention Physicians' Network N Engl J Med 342 2000 1156 1162
113. M.E. Martinez, S.M. Henning, D.S. Alberts Folate and colorectal neoplasia relation between plasma and dietary markers of folate and adenoma recurrence Am J Clin Nutr 79 2004 691 697
114. M. Vinceti, S. Rovesti, M. Bergomi The epidemiology of selenium and human cancer Tumori 86 2000 105 118
115. Y. Feng, J.W. Finley, C.D. Davis Dietary selenium reduces the formation of aberrant crypts in rats administered 3,2′-dimethyl-4-aminobiphenyl Toxicol Appl Pharmacol 157 1999 36 42
116. C.V. Rao, I. Cooma, J.G. Rodriguez Chemoprevention of familial adenomatous polyposis development in the APC(min) mouse model by 1,4-phenylene bis(methylene)selenocyanate Carcinogenesis 21 2000 617 621
117. L.C. Clark, G.F. Combs Jr, B.W. Turnbull Nutritional Prevention of Cancer Study Group Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial JAMA 276 1996 1957 1963
118. A. Umar, J.L. Viner, E.T. Hawk The future of colon cancer prevention Ann N Y Acad Sci 952 2001 88 108
119. B. Humar, D. D'Orazio, C. Albrecht Expression of putative anticancer targets in familial adenomatous polyposis and its association with the APC mutation status Int J Oncol 19 2001 1179 1186
120. P. Dolara, G. Caderni, L. Lancioni Aberrant crypt foci in human colon carcinogenesis Cancer Detect Prev 21 1997 135 140
121. M.A. Pereira, L.H. Barnes, V.L. Rassman Use of azoxymethane-induced foci of aberrant crypts in rat colon to identify potential cancer chemopreventive agents Carcinogenesis 15 1994 1049 1054
122. T. Takayama, S. Katsuki, Y. Takahashi Aberrant crypt foci of the colon as precursors of adenoma and cancer N Engl J Med 339 1998 1277 1284